Harrow Launches VEVYE Access For All, Reducing Patient Barriers for Dry Eye Disease Treatment

Harrow, a North American eyecare pharmaceuticals company, has introduced VEVYE Access For All, a new initiative designed to eliminate patient barriers to dry eye disease treatment. In collaboration with specialty pharmacy PhilRx, Harrow is offering VEVYE (cyclosporine ophthalmic solution) 0.1% at a flat price of $59 per bottle for eligible patients. This initiative ensures affordable, timely access to treatment, bypassing bureaucratic obstacles that often delay care.

Addressing Patient Access Challenges

Historically, access to dry eye disease treatments has been hampered by insurance restrictions, prior authorizations, and high costs. Through VEVYE Access For All, Harrow aims to create a seamless pathway for both eyecare professionals and patients.

Mark L. Baum, Chief Executive Officer of Harrow, emphasized the program’s mission:

“For too long, patients, doctors, and pharmaceutical companies have been at the mercy of unseen middlemen who act as access gatekeepers, using needless red tape to prevent patients from benefitting from medications they are prescribed. This program puts power back where it belongs – in the hands of eyecare professionals and their patients – by simplifying the prescribing and dispensing process and removing access impediments for all patients, creating a more frictionless path to therapy.”

Key Benefits of VEVYE Access For All

       • No prior authorizations required: Eliminating administrative delays.

       • Immediate prescription processing: Reducing wait times for treatment initiation.

       • Money-back guarantee: Offering confidence and security for patients.

Eyecare Professionals Applaud the Initiative

Eyecare providers are welcoming this step toward enhanced patient access. Dr. Ranjan P. Malhotra, a board-certified ophthalmologist with St. Louis-based Ophthalmology Associates, highlighted the importance of this program:

“As a cornea and refractive surgeon, I understand how critical a healthy ocular surface is to achieving superior surgical outcomes. With VEVYE Access For All, I can confidently prescribe VEVYE, knowing that my patients can start treatment quickly and at a price they can afford – without the burden of the growing number of insurance hurdles.”

Availability and Next Steps

The VEVYE Access For All program is available nationwide starting today. Physicians interested in enrolling their patients can send VEVYE prescriptions to PhilRx via electronic medical records (EMR), allowing eligible patients to receive discounted pricing and associated benefits through the pharmacy.

Looking forward, Harrow plans to expand this program to make it available at all pharmacies nationwide, ensuring even broader patient access to essential dry eye disease treatment.